Leveraging Technology to Cut Through the REMS Confusion

The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.

Download White Paper

You may also like:

Blog Post

Any clinician that has a role in medication therapy is affected by allergen screening. Common scenarios in which potential allergen interactions would need to be considered include: A physician entering a new ...

View Blog Post
Blog Post

Two years ago, I wrote a blog about health information exchange (HIE) and the role of the pharmacist in this important co...

View Blog Post
Blog Post

As we approach the midyear point, it’s a great opportunity to benchmark several key trends that are challenging both the pharmacy business and profession and compare them to the

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up